<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254409</url>
  </required_header>
  <id_info>
    <org_study_id>PRM151F-12GL</org_study_id>
    <nct_id>NCT01254409</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <acronym>PRM151F-12GL</acronym>
  <official_title>A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promedior, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promedior, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to assess safety, tolerability, the pharmacokinetic profile, and
      the pharmacodynamic profile of multiple doses of PRM-151 administered IV to IPF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease with a histological picture of
      usual interstitial pneumonia and a deteriorating clinical course. The prognosis is poor.
      Chronic alveolar inflammation with associated parenchymal remodeling is theorized to promote
      an ongoing abnormal fibrogenic repair response. Corticosteroids and immunomodulatory agents
      have not been shown to benefit IPF patients. Recently several published clinical studies have
      indicated a strong correlation between IPF severity and/or disease progression and the levels
      of specific plasma biomarker proteins related to epithelial cell health and extracellular
      matrix turnover.

      PRM-151 is being developed for potential therapeutic uses to prevent, treat, and reduce
      fibrosis.

      This study is the first intravenous multiple-dose study in humans, and will be conducted in
      patients with IPF. Patients will be randomized to receive either PRM-151 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>From first dose on Day 1 through Day 57</time_frame>
    <description>Number of subjects with Dose Limiting Toxicities, Number of Treatment Emergent Serious Adverse Events and Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 15</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 15</time_frame>
    <description>Time of Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC48</measure>
    <time_frame>Day 15</time_frame>
    <description>Area under the curve from 0 to 48 hrs post dose, with samples collected at 0.5, 0.75, 1, 1.5, 2, 3,4,6,8,12,16, 24 and 48 hours post Day 15 dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Day 15</time_frame>
    <description>Volume of Distribution at Steady State</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) Change From Baseline to Day 57</measure>
    <time_frame>Change from Day 1 (Baseline) to Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (Forced Vital Capacity) % Predicted Change From Baseline</measure>
    <time_frame>Day 1 (Baseline) and Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO (%) (Diffusing Capacity of Carbon Monoxide) Change From Baseline</measure>
    <time_frame>Day 1 (Baseline) and Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume 1sec )(%) Change From Baseline</measure>
    <time_frame>Day 1 (Baseline) and Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT (6 Minute Walk Test) Distance Walked Change From Baseline</measure>
    <time_frame>Screening (between Day -35 and Day 1) and Day 57</time_frame>
    <description>Change from baseline (measured during screening period) in distance walked during a 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ (St. George's Respiratory Questionnaire) Total Score Change From Baseline</measure>
    <time_frame>Day 1 (Baseline) and Day 57</time_frame>
    <description>St. George's Respiratory Questionnaire Total Score. Scores range from 0 (no impairment) to 100 (maximum impairment). A decrease in score represents a decrease in disease related symptoms. The SGRQ is not validated for IPF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PRM-151</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRM-151</intervention_name>
    <description>Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.</description>
    <arm_group_label>PRM-151</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of non-childbearing potential aged 40 to 80 years at screening.

          -  Diagnosis of idiopathic pulmonary fibrosis (IPF) as determined by high resolution
             computerized tomography (HRCT) and pulmonary function tests.

        Exclusion Criteria:

          -  History or presence of connective tissue disorder, tuberculosis (TB), cystic fibrosis,
             sarcoidosis, amyloidosis or other pulmonary disease except idiopathic pulmonary
             fibrosis (IPF).

          -  History or presence of chronic pulmonary obstructive disease, severe pulmonary
             hypertension, drug-induced pulmonary toxicity, other forms of idiopathic pneumonia, or
             interstitial lung diseases associated with environmental exposure medication or
             systemic disease.

          -  High resolution computerized tomography (HRCT) findings inconsistent with idiopathic
             pulmonary fibrosis(IPF).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Getsy, DMD, DO</last_name>
    <role>Study Director</role>
    <affiliation>Promedior, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>April 11, 2014</results_first_submitted>
  <results_first_submitted_qc>October 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2014</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary, fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="P2">
          <title>PRM-151 1 mg/kg</title>
          <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="P3">
          <title>PRM-151 5 mg/kg</title>
          <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="P4">
          <title>PRM-151 10 mg/kg</title>
          <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects enrolled in study</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="B2">
          <title>PRM-151 1 mg/kg</title>
          <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="B3">
          <title>PRM-151 5 mg/kg</title>
          <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="B4">
          <title>PRM-151 10 mg/kg</title>
          <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="12.88"/>
                    <measurement group_id="B2" value="63.7" spread="8.45"/>
                    <measurement group_id="B3" value="70.6" spread="8.26"/>
                    <measurement group_id="B4" value="66.5" spread="5.69"/>
                    <measurement group_id="B5" value="66.4" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC</title>
          <description>Forced Vital Capacity: volume of air that can forcibly be blown out after full inspiration, measured in liters</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.15" spread="0.64"/>
                    <measurement group_id="B2" value="2.96" spread="0.85"/>
                    <measurement group_id="B3" value="2.78" spread="0.73"/>
                    <measurement group_id="B4" value="2.97" spread="0.71"/>
                    <measurement group_id="B5" value="2.67" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC % Predicted</title>
          <description>The % of the FVC that would be predicted for a subject based on physical characteristics that influence the maximal inhalation: height, age, and gender.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="16.7"/>
                    <measurement group_id="B2" value="82.4" spread="15.5"/>
                    <measurement group_id="B3" value="80.0" spread="7.8"/>
                    <measurement group_id="B4" value="72.8" spread="14.3"/>
                    <measurement group_id="B5" value="74.1" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 % Predicted</title>
          <description>Forced Expiratory Volume 1 second: the volume of air expired in the first second during maximal expiratory effort. FEV1% predicted is the FEV1% of the patient divided by the average FEV1% in the population for any person of similar age, sex and body composition</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.8" spread="17.7"/>
                    <measurement group_id="B2" value="85.8" spread="16.8"/>
                    <measurement group_id="B3" value="87.0" spread="11.9"/>
                    <measurement group_id="B4" value="73.0" spread="12.1"/>
                    <measurement group_id="B5" value="78.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DLCO</title>
          <description>Diffusing capacity carbon monoxide is the carbon monoxide uptake from a single inspiration in a standard time (usually 10 seconds). DLCO% predicted is the % of the DLCO that would be predicted based on the subject's hemoglobin.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="8.4"/>
                    <measurement group_id="B2" value="41.2" spread="10.5"/>
                    <measurement group_id="B3" value="52.8" spread="9.8"/>
                    <measurement group_id="B4" value="46.0" spread="7.2"/>
                    <measurement group_id="B5" value="43.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>Number of subjects with Dose Limiting Toxicities, Number of Treatment Emergent Serious Adverse Events and Adverse Events</description>
        <time_frame>From first dose on Day 1 through Day 57</time_frame>
        <population>All subjects who received at least one dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Number of subjects with Dose Limiting Toxicities, Number of Treatment Emergent Serious Adverse Events and Adverse Events</description>
          <population>All subjects who received at least one dose of study treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose Limiting Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum concentration</description>
        <time_frame>Day 15</time_frame>
        <population>Subjects who received all doses of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum concentration</description>
          <population>Subjects who received all doses of study treatment</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="7.9"/>
                    <measurement group_id="O2" value="145" spread="41.9"/>
                    <measurement group_id="O3" value="225" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time of Maximum observed concentration</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time of Maximum observed concentration</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="10.4"/>
                    <measurement group_id="O2" value="1.30" spread="1.51"/>
                    <measurement group_id="O3" value="0.69" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC48</title>
        <description>Area under the curve from 0 to 48 hrs post dose, with samples collected at 0.5, 0.75, 1, 1.5, 2, 3,4,6,8,12,16, 24 and 48 hours post Day 15 dose.</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>AUC48</title>
          <description>Area under the curve from 0 to 48 hrs post dose, with samples collected at 0.5, 0.75, 1, 1.5, 2, 3,4,6,8,12,16, 24 and 48 hours post Day 15 dose.</description>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446" spread="118"/>
                    <measurement group_id="O2" value="2190" spread="1140"/>
                    <measurement group_id="O3" value="4710" spread="1180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life</title>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="14.0" upper_limit="29.3"/>
                    <measurement group_id="O2" value="43.6" lower_limit="11.2" upper_limit="79.2"/>
                    <measurement group_id="O3" value="71.6" lower_limit="32.8" upper_limit="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance</title>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance</title>
          <units>ml/hr/kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.17" upper_limit="3.48"/>
                    <measurement group_id="O2" value="1.59" lower_limit="0.780" upper_limit="2.65"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.749" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vss</title>
        <description>Volume of Distribution at Steady State</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Vss</title>
          <description>Volume of Distribution at Steady State</description>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" lower_limit="49.8" upper_limit="57.9"/>
                    <measurement group_id="O2" value="73.9" lower_limit="37.6" upper_limit="139.0"/>
                    <measurement group_id="O3" value="72.0" lower_limit="58.8" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) Change From Baseline to Day 57</title>
        <time_frame>Change from Day 1 (Baseline) to Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) Change From Baseline to Day 57</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.063" spread="0.116"/>
                    <measurement group_id="O2" value="0.058" spread="0.164"/>
                    <measurement group_id="O3" value="0.060" spread="0.074"/>
                    <measurement group_id="O4" value="0.078" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC (Forced Vital Capacity) % Predicted Change From Baseline</title>
        <time_frame>Day 1 (Baseline) and Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>FVC (Forced Vital Capacity) % Predicted Change From Baseline</title>
          <units>absolute change in % predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.3"/>
                    <measurement group_id="O2" value="2.4" spread="4.6"/>
                    <measurement group_id="O3" value="2.8" spread="3.0"/>
                    <measurement group_id="O4" value="1.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLCO (%) (Diffusing Capacity of Carbon Monoxide) Change From Baseline</title>
        <time_frame>Day 1 (Baseline) and Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>DLCO (%) (Diffusing Capacity of Carbon Monoxide) Change From Baseline</title>
          <units>Absolute change in % predicted DLCO</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.1"/>
                    <measurement group_id="O2" value="0.2" spread="3.3"/>
                    <measurement group_id="O3" value="-4.0" spread="6.8"/>
                    <measurement group_id="O4" value="-1.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume 1sec )(%) Change From Baseline</title>
        <time_frame>Day 1 (Baseline) and Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume 1sec )(%) Change From Baseline</title>
          <units>Absolute change in FEV1 % predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.3"/>
                    <measurement group_id="O2" value="2.6" spread="4.3"/>
                    <measurement group_id="O3" value="2.4" spread="1.1"/>
                    <measurement group_id="O4" value="0.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6MWT (6 Minute Walk Test) Distance Walked Change From Baseline</title>
        <description>Change from baseline (measured during screening period) in distance walked during a 6 minute walk test</description>
        <time_frame>Screening (between Day -35 and Day 1) and Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>6MWT (6 Minute Walk Test) Distance Walked Change From Baseline</title>
          <description>Change from baseline (measured during screening period) in distance walked during a 6 minute walk test</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="51"/>
                    <measurement group_id="O2" value="-11" spread="63"/>
                    <measurement group_id="O3" value="6" spread="43"/>
                    <measurement group_id="O4" value="35" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SGRQ (St. George's Respiratory Questionnaire) Total Score Change From Baseline</title>
        <description>St. George's Respiratory Questionnaire Total Score. Scores range from 0 (no impairment) to 100 (maximum impairment). A decrease in score represents a decrease in disease related symptoms. The SGRQ is not validated for IPF.</description>
        <time_frame>Day 1 (Baseline) and Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 1 mg/kg</title>
            <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O3">
            <title>PRM-151 5 mg/kg</title>
            <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
          <group group_id="O4">
            <title>PRM-151 10 mg/kg</title>
            <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>SGRQ (St. George's Respiratory Questionnaire) Total Score Change From Baseline</title>
          <description>St. George's Respiratory Questionnaire Total Score. Scores range from 0 (no impairment) to 100 (maximum impairment). A decrease in score represents a decrease in disease related symptoms. The SGRQ is not validated for IPF.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="6.2"/>
                    <measurement group_id="O2" value="2.3" spread="17.9"/>
                    <measurement group_id="O3" value="7.1" spread="12.0"/>
                    <measurement group_id="O4" value="-6.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0.9% saline administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="E2">
          <title>PRM-151 1 mg/kg</title>
          <description>PRM-151 1 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="E3">
          <title>PRM-151 5 mg/kg</title>
          <description>PRM-151 5 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
        <group group_id="E4">
          <title>PRM-151 10 mg/kg</title>
          <description>PRM-151 10 mg/kg administered as a 30 minute IV infusion Days 1, 3, 5, 8 and 15</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Catheter site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators agree that the first public presentation of data will be a joint, multicentre publication of results. If this does not occur within 12 months after conclusion of the study, investigator may publish the results, provided that the complete manuscript or other publication is submitted to the sponsor for review 30 days prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth G. Trehu, MD</name_or_title>
      <organization>Promedior, Inc.</organization>
      <phone>781-538-4203</phone>
      <email>btrehu@promedior.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

